Adma Biologics Inc (ADMA) President and CEO Adam S Grossman Bought $120,000 of Shares
May 21, 2019 | About: ADMA +0%
GuruFocus has detected 2 Warning Signs with ADMA Biologics Inc adma.
Piotroski F-Score: Low
Revenue per Share: Declined
President and CEO of Adma Biologics Inc (NASDAQ:ADMA) Adam S Grossman bought 30,000 shares of ADMA on 05/17/2019 at an average price of $4 a share. The total cost of this purchase was $120,000.
ADMA Biologics Inc is a biopharmaceutical company. The company develops and manufactures specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases. ADMA Biologics Inc has a market cap of $193.870 million; its shares were traded at around $4.18 with and P/S ratio of 11.50. ADMA Biologics Inc had annual average EBITDA growth of 8.50% over the past five years.
CEO Recent Trades:
President and CEO Adam S Grossman bought 30,000 shares of ADMA stock on 05/17/2019 at the average price of $4. The price of the stock has increased by 4.5% since.
Warning! GuruFocus has detected 2 Warning Signs with ADMA. Click here to check it out.
ADMA 30-Year Financial Data
The intrinsic value of ADMA
Peter Lynch Chart of ADMA
CFO Recent Trades:
EVP, CFO Brian Lenz bought 5,000 shares of ADMA stock on 05/17/2019 at the average price of $4. The price of the stock has increased by 4.5% since.
Directors and Officers Recent Trades:
Director Jerrold B Grossman bought 12,000 shares of ADMA stock on 05/17/2019 at the average price of $4. The price of the stock has increased by 4.5% since.
Director Lawrence P. Guiheen bought 25,000 shares of ADMA stock on 05/17/2019 at the average price of $4. The price of the stock has increased by 4.5% since.
EVP, CSO and CMO James Mond bought 4,500 shares of ADMA stock on 05/17/2019 at the average price of $4. The price of the stock has increased by 4.5% since.
That is a great sign when insiders are buying up their own offerings. I am sure they were very happy with the two FDA approvals they just got.